

04 Jun 2024 | Analysis

China Biotech Podcast: Going Global Trends, Rare Disease Drug Development

Internationalization 'A Must' for China Biotechs

by Brian Yang

Guest speaker Professor Guangzuo Luo joins Brian Yang and Dexter Yang to discuss orphan drug development and going global trends for Chinese bioventures, along with the latest business moves from Shanghai Fosun and Jiangsu Hengrui.

This time, Guangzuo Luo, founder and chief scientific officer of Nanjing-based Bioncetech, joins China-based *Scrip* editors Brian Yang and Dexter Yan in this Chinese-language podcast to talk about his views on the challenges and opportunities around developing orphan drugs in China.

Luo is also a professor at China Medical University and has years of experience developing gene therapies, including the first US-approved adeno-associated virus-based gene therapy, *Spark Therapeutics*, *Inc.*'s Luxturna (voretigene neparvovec) for an inherited retinal disease.

He also discusses Bioncetech's pipeline, which includes candidates for common conditions.

In the second part of the podcast, Brian talks about his coverage of recent moves by <u>Jiangsu</u> <u>Hengrui Medicine Co., Ltd.</u> and <u>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</u> to go global.

He highlights the three main options for Chinese biotechs pursuing internationalization, other recent trends and how a full acquisition of *Shanghai Henlius Biotech Co. Ltd.* by Fosun might benefit the latter's overseas expansion goals.



Stories discussed in this podcast:

(Also see "China Rare Disease Firms Aspire To Global Stage" - Scrip, 30 May, 2024.)

(Also see "Fosun To Fully Acquire Henlius In Go-Global Push?" - Scrip, 26 May, 2024.)

Click here to explore this interactive content online